PHASE 2 STUDY OF ADXS11-001 IN SUBJECTS WITH PERSISTENT/RECURRENT, LOCO-REGIONAL OR METASTATIC ANAL CANCER OR HPV+ SQUAMOUS CELL CANCER OF THE RECTUM

Trial Profile

PHASE 2 STUDY OF ADXS11-001 IN SUBJECTS WITH PERSISTENT/RECURRENT, LOCO-REGIONAL OR METASTATIC ANAL CANCER OR HPV+ SQUAMOUS CELL CANCER OF THE RECTUM

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Axalimogene filolisbac (Primary)
  • Indications Anal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FAWCETT
  • Sponsors Advaxis
  • Most Recent Events

    • 13 Jun 2017 Results from Stage 1 published in an Advaxis Media Release
    • 13 Jun 2017 According to an Advaxis media release, Dr. Eng is the principal investigator of this study.
    • 13 Jun 2017 According to an Advaxis media release, an update from this trial presented at annual Investor & Analyst Day.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top